Publication | Open Access

An Intermediate Alemtuzumab Schedule Reduces the Incidence of Mixed Chimerism Following Reduced-Intensity Conditioning Hematopoietic Cell Transplantation for Hemophagocytic Lymphohistiocytosis

Lymphoid NeoplasiaCell TherapyTransplantationIntermediate Alemtuzumab ScheduleHematologyImmunologyAutoimmunityMixed ChimerismHemophagocytic LymphohistiocytosisMedicineCell Transplantation